These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


81 related items for PubMed ID: 3379335

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Hyperamylasemia in endometrial adenocarcinoma].
    Matsuta M, Murakami K, Ono H, Saitoh S, Nishiya I, Takayama K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1557-64. PubMed ID: 2479698
    [Abstract] [Full Text] [Related]

  • 5. [Creatine kinase BB and neuron specific r-enolase as biomarkers for lung cancer].
    Usui A, Fujita K, Imaizumi M, Abe T, Inoue K, Matsumoto S, Kato K.
    Gan No Rinsho; 1987 Nov; 33(14):1763-70. PubMed ID: 2826840
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is NSE truly a useful marker in NSCLC?
    Ishikawa H, Satoh H, Sekizawa K.
    Lung Cancer; 2004 May; 44(2):267; author reply 269. PubMed ID: 15084392
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 May; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 12. [Diagnostic value of pleural effusion carcinoembryonic antigen, squamous cell carcinoma related antigen and neuron-specific-enolase in patients with lung cancer].
    Fujii M, Kiura K, Kamei H, Segawa Y.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1988 May; 26(5):519-23. PubMed ID: 2852270
    [No Abstract] [Full Text] [Related]

  • 13. [Tumor markers. II. Their significance in the follow-up of patients after radical resection of lung neoplasms].
    Ratto GB, Capponi G, De Grandi R, Augeri C, Secco GB, Fardelli R.
    Minerva Chir; 1990 Oct 31; 45(20):1273-80. PubMed ID: 2082204
    [Abstract] [Full Text] [Related]

  • 14. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Oct 31; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B, Fernández Fernández M, Suárez B, Allende MT.
    Rev Clin Esp; 1992 Mar 31; 190(4):209. PubMed ID: 1589619
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical evaluation of serum neuron-specific enolase as a tumor marker in lung cancer].
    Yonei T, Ohnoshi T, Hiraki S, Yamashita H, Ishii J, Egawa T, Kozuka A, Moritaka T, Uji H, Yoshida M.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1988 Feb 31; 26(2):139-44. PubMed ID: 2841525
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.